Treatments
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that a reduction in plasma neurofilament light (NfL) concentration is “reasonably likely” to predict clinical benefit of tofersen…
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that a reduction in plasma neurofilament light (NfL) concentration is “reasonably likely” to predict clinical benefit of tofersen…